Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and Deoxyribonuclease (human clone protein moiety); Dornasa alfa. Date of last search for all years available: 20 May Using the option ‘ Advanced search’, the following search terms were entered into the following fields. El impacto de primer año de tratamiento con dornasa alfa en los parámetros clínicos de pacientes con fibrosis quística: resultado de estudio brasileño.
|Published (Last):||14 July 2010|
|PDF File Size:||19.31 Mb|
|ePub File Size:||19.59 Mb|
|Price:||Free* [*Free Regsitration Required]|
Why is this medication prescribed? We described the clinical characteristics and outcomes of the patients included in the Brazilian Cystic Fibrosis Quality of Life Trial Ask your pharmacist any questions you have about refilling your prescription.
However, the outcomes were possibly confounded by those receiving combination therapies, varying primary diagnoses, and varying end points evaluated.
Dornase Alfa: MedlinePlus Drug Information
Patients were analyzed according to the age-groups 14 A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
Comparison between three or more means was performed using the analysis of variance. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis: Fortunately, improvements in age at diagnosis has been observed in recent Brazilian research Cystic Fibrosis Foundation consensus report.
Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot wlfa them. The significant improvement in the Shwachman-Kulczychi score observed in the older group can also be pointed as a positive outcome of the therapy, and when considered together with the favorable results in CFQ-R other domains 14it allows the conclusion that dornase alfa is an additional therapeutic option for CF.
Extracellular DNA aalfa a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction. The formal inclusion of CFQ-R questionnaires as a clinical outcome was essential, as it detected the impact of dornase alfa treatment over QoL, from the perspective of patients and their families. In addition, treatment with dornase alfa for 6 and 12 months was not associated with significant changes in pulmonary function parameters, with the exception of Shwachman-Kulczychi score that showed a significant improvement after 6 months of dornase alfa Table 3.
Received Nov 22; Accepted May Before you use dornase alfa the first time, read the written instructions that come with it. Dornase alfa may be considered as a therapeutic option in non-cystic fibrosis pediatric patients with pulmonary atelectasis, who require treatment intervention when conventional therapy is unsuccessful.
This article has been cited by other articles in PMC. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. The majority of patients experienced improvement in atelectasis, suggesting benefit after receiving treatment with dornase alfa.
Patients aged 6 to 11 years were those who most benefited from the use of dornase alfa. Monaldi Arch Chest Dis.
Dornase alfa is used to treat cystic fibrosis but does not cure it. From Wikipedia, the free encyclopedia. Table 5 Use of routine concomitant treatments during the study follow-up. In all age groups, P. Journal List Rev Paul Pediatr v.
Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to these infections. What side effects can this medication cause? A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Do not use more or less of it or use it more often than prescribed by your doctor. Use dornase alfa exactly as directed.
Dornase Alfa for Non-Cystic Fibrosis Pediatric Pulmonary Atelectasis.
In qlfa, sputum DNase levels declined below half of those detected immediately post-administration within 2 hours but effects on sputum rheology persisted beyond 12 hours. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, alfq dornase alfa use.
A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period. Use the missed dose as soon as you remember it.